Iptratropium Bromide Infectopharm Arzneimittel Und Consilium (Ipratropium Bromide)

• Ipratropium bromide is used to manage nasal symptoms by blocking muscarinic receptors in the nasal mucosa.
• Allergic rhinitis: reduces nasal congestion, rhinorrhea, and sneezing in patients with seasonal or perennial allergies.
• Non‑allergic rhinitis: alleviates chronic nasal blockage and watery discharge unrelated to allergens.
• Rhinitis associated with upper‑respiratory infections: provides symptomatic relief of nasal stuffiness during common colds.

• Ipratropium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (M1 and M3) located on the nasal epithelium and submucosal glands. By blocking these receptors, it inhibits parasympathetic‑mediated secretion of mucus and vasodilation, leading to reduced nasal secretions and decreased mucosal edema, which eases congestion.

Ipratropium bromide is generally well tolerated, but some patients may experience local or systemic reactions.

Common Side Effects

• Nasal irritation or burning sensation
• Dryness of the nasal mucosa
• Unpleasant taste or throat irritation
• Cough or mild bronchospasm
• Headache
• Sneezing

Serious or Rare Side Effects

• Paradoxical worsening of nasal obstruction
• Severe bronchospasm, especially in patients with underlying asthma
• Allergic reactions such as rash, urticaria, or angioedema
• Dizziness or faintness
• Vision changes related to anticholinergic effect
• Rare systemic anticholinergic toxicity (e.g., confusion, urinary retention)

• Before using ipratropium bromide nasal spray, consider the following safety measures.
• Allergy: Do not use if you have known hypersensitivity to ipratropium bromide or other anticholinergics.
• Glaucoma: Use with caution in patients with narrow‑angle glaucoma.
• Asthma: Monitor closely in individuals with severe asthma or reactive airway disease.
• Pediatric use: Not recommended for children under two years of age unless specifically prescribed.
• Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Ipratropium bromide may interact with other medications that possess anticholinergic activity or affect nasal physiology.

Major Interactions (Avoid)

• Concurrent use of multiple anticholinergic nasal agents, which can increase systemic anticholinergic load.
• Use with other muscarinic antagonists (e.g., tiotropium) without medical supervision.

Moderate Interactions (Monitor Closely)

• Combination with antihistamines may enhance sedation or dry‑mouth effects.
• Concurrent ophthalmic anticholinergic drops may increase systemic exposure.
• Use with beta‑agonist inhalers generally safe but monitor for bronchospasm.
• Caution when combined with monoamine oxidase inhibitors; monitor for unexpected nasal irritation.